Drug Trial Radar · NCT06389487
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above
Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,459
Actual
Start
Apr 29, 2024
Primary completion
Jul 29, 2024
Study completion Mar 18, 2025
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The aim of this study is to demonstrate the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in non-immunocompromised adults 18-49 years of age (YOA), who are at increased risk (AIR) for RSV disease, compared to older adults (OA) 60 YOA and above.
Conditions
- Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccineBiological
1 dose of RSVPreF3 OA investigational vaccine is administered intramuscularly on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: RSV-A Neutralizing Titers Expressed as Group Geometric Mean Titers (GMTs)Time frame: At Day 31
- Part A: Percentage of Participants With Seroresponse Rate (SRR) in RSV-A Neutralizing TitersTime frame: Day 31 compared with baseline (Day 1)
- Part A: RSV-B Neutralizing Titers Expressed as Group GMTsTime frame: At Day 31
- Part A: Percentage of Participants With SRR in RSV-B Neutralizing TitersTime frame: Day 31 compared with baseline (Day 1)
Locations
52 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Glendale, Arizona
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
North Hollywood, California
GSK Investigational Site
Oakland, California
GSK Investigational Site
Walnut Creek, California
GSK Investigational Site
Hialeah, Florida
GSK Investigational Site
North Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Silver Spring, Maryland
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Oklahoma City, Oklahoma
GSK Investigational Site
Knoxville, Tennessee
GSK Investigational Site
DeSoto, Texas
GSK Investigational Site
Charlottesville, Virginia
GSK Investigational Site
Wenatchee, Washington
GSK Investigational Site
Coffs Harbour, New South Wales, Australia
GSK Investigational Site
Sydney, New South Wales, Australia
GSK Investigational Site
Sydney, New South Wales, Australia
GSK Investigational Site
Fortitude Valley, Queensland, Australia
GSK Investigational Site
Tarragindi, Queensland, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
St Albans, Victoria, Australia
GSK Investigational Site
New Westminster, British Columbia, Canada
GSK Investigational Site
Victoria, British Columbia, Canada
GSK Investigational Site
Truro, Nova Scotia, Canada
GSK Investigational Site
Greater Sudbury, Ontario, Canada
GSK Investigational Site
Guelph, Ontario, Canada
GSK Investigational Site
London-Ontario, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Saint-Charles-Borromée, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Essen, Germany
GSK Investigational Site
Mainz, Germany
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.